Phospholipase A2, Lipoprotein Associated (LpPLA2) Recombinant Protein | LpPLA2 recombinant protein

Recombinant Phospholipase A2, Lipoprotein Associated (LpPLA2)

Cat. Num. AAA2010829

• Gene Names: PLA2G7; PAFAD; PAFAH; LP-PLA2; LDL-PLA2
• Applications: SDS-Page, Western Blot, ELISA, Immunoprecipitation
• Purity: >95%
• Synonyms: Phospholipase A2; Lipoprotein Associated (LpPLA2); Recombinant Phospholipase A2; LpPLA2 recombinant protein

• Host: E Coli
• Purity/Purification: >95%
• Form/Format: Supplied as lyophilized form in PBS, pH7.4, containing 1mM DTT, 5% trehalose, 0.05% sarcosyl and preservative.
• Sequence: The sequence of the target protein is listed below.; FDWQYINPV AHMKSSAWVN KIQVLMAAAS FGQTKIPRGN GPYSVGCTDL MFDHTNKGTF LRLYYPSQDN DRLDTLWIPN KEYFWGLSKF LGTHWLMGNI LRLLFGSMTT PANWNSPLRP GEKYPLVVFS HGLGAFRTLY SAIGIDLASH GFIVAAVEHR DRSASATYYF KDQSAAEIGD KSWLYLRTLK QEEETHIRNE QVRQRAKECS QALSLILDID HGKPVKNALD LKFDMEQLKD SIDREKIAVI GHSFGGATVI QTLSEDQRFR CGIALDAWMF PLGDEVYSRI PQPLFFINSE YFQYPANIIK MKKCYSPDKE RKMITIRGSV HQNFADFTFA TGKIIGHMLK LKGDIDSNVA IDLSNKASLA FLQKHLGLHK DFDQWDCLIE GDDENLIPGT NINTTNQHIM LQNSSGIEKY N
• Sequence Length: 441

• Applicable Applications for LpPLA2 recombinant protein: SDS-PAGE, Western Blot (WB), ELISA (EIA), Immunoprecipitation (IP)
• Organism: Homo sapiens (Human)
• Expression System: Prokaryotic expression
• Residues: Phe22~Asn441 (Accession # Q13093) with N-terminal His-Tag
• Subcellular Location: Secreted, extracellular space
• Endotoxin Level: <1.0EU per 1ug (determined by the LAL method)
• Predicted Isoelectric Point: 7.1
• Reconstitution: Reconstitute in sterile ddH2O.
• Preparation and Storage: Avoid repeated freeze/thaw cycles. Store at 2-8 degree C for one month. Aliquot and store at -80 degree C for 12 months.; Stability Test: The thermal stability is described by the loss rate of the targetprotein. The loss rate was determined by accelerated thermal degradation test,that is, incubate the protein at 37 degree C for 48h, and no obvious degradation andprecipitation were observed. (Referring from China Biological Products Standard,which was calculated by the Arrhenius equation.) The loss of this protein is lessthan 5% within the expiration date under appropriate storage condition.

SDS-Page

NCBI and Uniprot Product Information

• NCBI GI #: 270133071
• NCBI GeneID: 7941
• NCBI Accession #: NP_001161829.1
• NCBI GenBank Nucleotide #: NM_001168357.1
• UniProt Accession #: Q13093; Q15692; Q5VTT1; Q8IVA2; A5HTT5
• Molecular Weight: 50.0kDa
• NCBI Official Full Name: platelet-activating factor acetylhydrolase
• NCBI Official Synonym Full Names: phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma)
• NCBI Official Symbol: PLA2G7
• NCBI Official Synonym Symbols: PAFAD; PAFAH; LP-PLA2; LDL-PLA2
• NCBI Protein Information: platelet-activating factor acetylhydrolase; LDL-PLA(2); gVIIA-PLA2; PAF 2-acylhydrolase; PAF acetylhydrolase; group-VIIA phospholipase A2; LDL-associated phospholipase A2; lipoprotein-associated phospholipase A2; 1-alkyl-2-acetylglycerophosphocholine esterase; 2-acetyl-1-alkylglycerophosphocholine esterase
• UniProt Protein Name: Platelet-activating factor acetylhydrolase
• UniProt Gene Name: PLA2G7
• UniProt Synonym Gene Names: PAFAH; PAF acetylhydrolase; gVIIA-PLA2; LDL-PLA(2)
• UniProt Entry Name: PAFA_HUMAN

NCBI Description

The protein encoded by this gene is a secreted enzyme that catalyzes the degradation of platelet-activating factor to biologically inactive products. Defects in this gene are a cause of platelet-activating factor acetylhydrolase deficiency. Two transcript variants encoding the same protein have been found for this gene.[provided by RefSeq, Dec 2009]

Uniprot Description

PLA2G7: Modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. Has a specificity for substrates with a short residue at the sn-2 position. It is inactive against long-chain phospholipids. Defects in PLA2G7 are the cause of platelet-activating factor acetylhydrolase deficiency (PAFAD). An enzymatic deficiency that results in exacerbated bodily response to inflammatory agents. Asthmatic individuals affected by this condition may manifest severe respiratory symptoms. Defects in PLA2G7 are a cause of susceptibility to asthma (ASTHMA). The most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. It is characterized by recurrent attacks of paroxysmal dyspnea, with weezing due to spasmodic contraction of the bronchi. PLA2G7 variants can be a risk factor for the development of asthma and PLA2G7 may act as a modifier gene that modulates the severity of this disease. Defects in PLA2G7 are a cause of susceptibility to atopic hypersensitivity (ATOPY). A condition characterized by predisposition to develop hypersensitivity reactions. Atopic individuals can develop eczema, allergic rhinitis and allergic asthma. Belongs to the AB hydrolase superfamily. Lipase family.

Protein type: EC 3.1.1.47; Hydrolase; Secreted; Lipid Metabolism - ether lipid; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 6p21.2-p12

Cellular Component: cytoplasm; extracellular region

Molecular Function: calcium-independent phospholipase A2 activity; phospholipid binding; 1-alkyl-2-acetylglycerophosphocholine esterase activity

Biological Process: cellular protein metabolic process; lipid catabolic process; positive regulation of inflammatory response

Disease: Asthma, Susceptibility To; Ige Responsiveness, Atopic; Platelet-activating Factor Acetylhydrolase Deficiency